Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) insider Amar Murugan sold 3,913 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $10,721.62. Following the completion of the sale, the insider now directly owns 121,587 shares of the company's stock, valued at approximately $333,148.38. This trade represents a 3.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Acelyrin Trading Down 1.1 %
NASDAQ:SLRN opened at $2.79 on Thursday. The company has a market capitalization of $279.91 million, a P/E ratio of -1.13 and a beta of 1.25. Acelyrin, Inc. has a 12 month low of $1.85 and a 12 month high of $8.59. The firm has a fifty day simple moving average of $2.26 and a 200-day simple moving average of $3.84.
Acelyrin (NASDAQ:SLRN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07. Equities analysts forecast that Acelyrin, Inc. will post -2.53 EPS for the current year.
Institutional Investors Weigh In On Acelyrin
A number of institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC lifted its stake in Acelyrin by 28.5% during the 4th quarter. ProShare Advisors LLC now owns 25,307 shares of the company's stock valued at $79,000 after acquiring an additional 5,617 shares during the period. Wells Fargo & Company MN raised its stake in shares of Acelyrin by 21.9% during the 4th quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock valued at $163,000 after buying an additional 9,332 shares during the last quarter. Virtu Financial LLC acquired a new stake in Acelyrin during the third quarter worth about $50,000. HighTower Advisors LLC purchased a new position in Acelyrin during the third quarter valued at approximately $50,000. Finally, XTX Topco Ltd acquired a new position in Acelyrin in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 87.31% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have commented on SLRN. HC Wainwright cut their target price on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Wells Fargo & Company reduced their price target on Acelyrin from $15.00 to $13.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 11th. Finally, Citigroup lowered their price objective on Acelyrin from $6.00 to $3.00 and set a "neutral" rating for the company in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $9.60.
Get Our Latest Research Report on SLRN
About Acelyrin
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
